Highest-materiality recent filing
Haemonetics acquires Vivasure Medical for up to €185M; upfront €100M plus €85M earn-out
Acquired all equity of Vivasure Medical, a Galway, Ireland-based developer of percutaneous vessel closure technology.
Haemonetics completes sale of whole blood assets to GVS for up to $67.8M
Total cash consideration up to $67.8M: $45.3M upfront (adjusted) plus up to $22.5M contingent.
Haemonetics sells whole blood assets to GVS for $44.6M cash plus up to $22.5M earnout
Total consideration up to $67.1M: $44.6M cash at close plus up to $22.5M contingent on sales growth and milestones.
Issued $700M (incl. $100M greenshoe) of 2.50% Convertible Senior Notes due June 1, 2029.
Haemonetics prices $600M 2.50% convertible notes due 2029; to repurchase $200M of 2026 notes
$600M 2.50% convertible senior notes due 2029 priced; initial conversion price ~$117.12/share (30% premium over $90.09 closing).
Haemonetics enters $1B credit agreement; $250M term loan, $750M revolver due 2029
New $250M senior unsecured term loan retires existing term loan under 2022 credit agreement.
Haemonetics to acquire Attune Medical for $160M upfront; device complements EP portfolio
Upfront cash $160M plus contingent consideration based on sales growth and milestones.
Haemonetics closes acquisition of OpSens Inc.
Acquisition of OpSens Inc. closed on December 12, 2023, as previously announced.
Haemonetics to acquire OpSens for $2.90/share cash via arrangement
Haemonetics to acquire all outstanding shares of OpSens via plan of arrangement under Quebec Business Corporations Act.
Haemonetics to acquire OpSens for CAD $2.90/share in cash, expected close by March 31, 2024
Haemonetics (HAE) will pay CAD $2.90 per share for all OpSens common shares via a plan of arrangement under Québec law.
Haemonetics Q3 fiscal 2023 adjusted EPS $0.82, revenue $298.1M; raises full-year guidance
Q3 revenue $298.1M (+2.1% reported, -0.1% organic); GAAP EPS $0.37, adjusted EPS $0.82 vs $0.73 prior year.
New $420M revolving credit facility (up from $350M) and $280M term loan to replace existing term loan.
Haemonetics appoints James D'Arecca as CFO effective April 11, 2022; Burke to retire
James D'Arecca appointed CFO effective April 11, 2022; William Burke steps down as CFO on that date.
On April 27, 2026, Charles J. Dockendorff informed Haemonetics Corporation (the “Company”) that he will not stand for re-election at the Company’s 2026 Annual Meeting of Shareholders (the “2026 Annual Meeting”).
On March 3, 2025, Haemonetics Corporation (the “Company”) announced the appointment of Frank W. Chan, Ph.D. as its Executive Vice President, Chief Operating Officer, effective April 7, 2025.
Josep Llorens, Executive Vice President, Global Manufacturing and Supply Chain, has notified Haemonetics Corporation (the “Company”) of his decision to retire from the Company effective July 11, 2025.
Anila Lingamneni, Executive Vice President, Chief Technology Officer, will leave Haemonetics Corporation (the “Company”) on November 1, 2024.
On August 4, 2023, the Board of Directors of Haemonetics Corporation (the “Company”) elected Diane M. Bryant as a director of the Company, effective immediately.
Ms. Farris, age 47, joined the Company as Vice President, Chief Accounting Officer on October 17, 2022.
On August 5, 2022, the Board of Directors of Haemonetics Corporation (the “Company”) appointed James C. D’Arecca, Executive Vice President, Chief Financial Officer, as the Company’s principal accounting officer
On June 16, 2022, Haemonetics Corporation (the “Company”) announced that Michelle L. Basil, Executive Vice President, General Counsel has decided to transition from the Company effective October 31, 2022.
Dan Goldstein, Vice President, Corporate Controller and Principal Accounting Officer will leave Haemonetics Corporation (the “Company”) on August 9, 2022.
On March 21, 2022, the Company announced the appointment of James C. D’Arecca as its Chief Financial Officer, effective April 11, 2022.
Mr. Burke will step down as Chief Financial Officer and principal financial officer of the Company on April 11, 2022
William P. Burke, Executive Vice President, Chief Financial Officer (“CFO”) has decided to retire from the Company in June 2022.
Max materiality 0.75 · Median 0.40 · Most common event earnings